NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts http://www.reportlinker.com/p01158474/MediPoint-Predictive-Breast-Cancer-Gene-Testing---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts

Summary

Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics. Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutations. By the end of our forecast period, the competitive landscape will experience significant change due to the erosion of Myriad Genetics' position, as a result of the expiry of key patents, and the emergence of alternative molecular technologies.

This report focuses on the predictive breast cancer gene testing markets in Europe (France, Germany, Italy, Spain, and the UK), and identifies unmet needs in the market, physician attitudes towards current gene testing, and the future of gene testing in the face of rapid technological advancement.

Scope

- An overview of Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized EU Breast Cancer Gene Testing market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018. - Investigation of current and future market competition for Breast Cancer Gene Testing - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of EU device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as oncologists

Reasons to buy

- Understand the trends shaping and driving EU Breast Cancer Gene Testing Market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in EU Breast Cancer Gene Testing Market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. - What's the next big thing in EU Breast Cancer Gene Testing market landscape? Identify, understand and capitalize.

Go here to see the original:
MediPoint: Predictive Breast Cancer Gene Testing - EU Analysis and Market Forecasts

Recommendation and review posted by Bethany Smith

NEW YORK, April 11, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts http://www.reportlinker.com/p01158473/MediPoint-Predictive-Breast-Cancer-Gene-Testing---US-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

MediPoint: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts

Summary

Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics. Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutations. By the end of our forecast period, the competitive landscape will experience significant change due to the erosion of Myriad Genetics' position, as a result of the expiry of key patents, and the emergence of alternative molecular technologies.

This report focuses on the predictive breast cancer gene testing markets in the US and identifies unmet needs in the market, physician attitudes towards current gene testing, and the future of gene testing in the face of rapid technological advancement.

Scope

- An overview of Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines. - Annualized US Breast Cancer Gene Testing market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018. - Investigation of current and future market competition for Breast Cancer Gene Testing - Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events. - Competitor assessment including device approval analysis and device sales forecasts. - Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast. - Analysis of unmet needs within the market and opportunities for future players. - Technology trends evaluation to assess strength of pipeline. - An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines. - Company profiles including business description, financial overview and SWOT analysis. - Coverage of key market players. - Strategic assessment of the US device sector through market impact analysis, future market scenario and company analysis. - Direct quotes from Key Opinion Leaders (KOL) as well as oncologists

Reasons to buy

- Understand the trends shaping and driving the US Breast Cancer Gene Testing Market. - Realize device preferences of physicians who have performed the tests already. - Access market sizing, forecasts and quantified growth opportunities in the US Breast Cancer Gene Testing Market through 2018. - Quantify candidate patient populations to better design product pricing & launch plans. - Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape. - Perform benchmarking analysis of growth opportunities against currently marketed products. - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market. - Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth. - What's the next big thing in the US Breast Cancer Gene Testing market landscape? Identify, understand and capitalize.

See original here:
MediPoint: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts

Recommendation and review posted by Bethany Smith

WATERTOWN, Mass.--(BUSINESS WIRE)--

Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced the publication of new research findings in the journal Cell. The research validates the approach of mapping and targeting newly identified gene control domains, known as Super-Enhancers, for drug discovery and development in cancer and other diseases. The discovery of Super-Enhancers is the basis of Syros' unique platform to identify and modulate pivotal events in disease pathogenesis and critical disease-driver targets.

Syros Co-founder Richard A. Young, Ph.D., who is a Member of the Whitehead Institute, and Professor of Biology at Massachusetts Institute of Technology, led the groundbreaking gene control research. Syros Co-founder James E. (Jay) Bradner, M.D., Assistant Professor of Medicine, Harvard Medical School and Investigator, Department of Medical Oncology, Dana Farber Cancer Institute, co-authored the research, which was funded by the National Institutes of Health and the National Cancer Institute. Syros recently completed a licensing agreement with the Whitehead Institute and the Dana Farber Cancer Institute for intellectual property related to this gene control discovery and other gene control technologies and assets.

Given the complexity of gene expression, the discovery of a small number of powerful gene control regulators provides a promising and exciting new approach to understanding key determinants of cell identity in normal and disease states, said Dr. Young. We have identified Super-Enhancers with key cancer driving genes in all tumors studied and have demonstrated that we can selectively disrupt these genes through inhibition of enhancer factors.

The new research published in back-to-back papers in Cell uncovered that master transcription factors form powerful gene control regulators, called Super-Enhancers, at key cell identity genes; that Super-Enhancers differ from enhancers in their size, transcription factor density and content; that the repertoire of genes that they regulate is unique to each cell type; and that they are important switches for driving cell type specific gene expression programs. In one of the research papers, Super-Enhancers were identified in cancer cells associated with key oncogene drivers and disruption of Super-Enhancers by inhibition of enhancer factors resulted in a preferential inhibition of Super-Enhancer driven genes. The papers, Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers1 and Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes,2 are published in the April 11th print edition of Cell and available online.

This research, which highlights discovery of the master switches for genes critical in disease, gives Syros a completely new approach to identify and modulate disease driver genes, said Nancy Simonian, M.D., Syros Chief Executive Officer. We look forward to translating the pioneering research of Drs. Young and Bradner into therapeutics that can help people facing a variety of diseases, especially cancer.

Syros also announced today the closing of a $30 million Series A financing led by ARCH Venture Partners and Flagship Ventures. Other investors include WuXi PharmaTech Corporate Venture Fund, and undisclosed private investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals is a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros initial focus is in cancer, but the company platform will also be applicable to other therapeutic areas. The Companys founders are pioneers in gene control research and translation. Co-founded and backed by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Watertown, MA. For more information, visit http://www.syros.com.

1 Loven, J., Hoke, H., Yin, C., Lau, A., Orlando, D., Vakoc, C., Bradner, J., Lee, T. & Young, R. (2013). Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell, 153(2).

Read more:
Syros Pharmaceuticals Announces Publications in Cell Related to Key Gene Control Discovery

Recommendation and review posted by Bethany Smith

Genetic engineering with cabbages
Ellie, Ari, and cabbages.

By: ELLIEISDEADLY

See more here:
Genetic engineering with cabbages - Video

Recommendation and review posted by Bethany Smith

Feed The Beast [Minecraft Modpack] [HD|German] # 1 - Start mit nicem Biom 😀
Kanal: http://www.youtube.com/user/Cezesslp mit dabei: http://www.youtube.com/user/Byntor Minecraft Modpack by Feed the Beast Team: http://www.feed-the-beast...

By: CezessLP

Read this article:
Feed The Beast [Minecraft Modpack] [HD|German] # 1 - Start mit nicem Biom 😀 - Video

Recommendation and review posted by Bethany Smith

Public release date: 10-Apr-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 10, 2013New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. A novel nanoparticle-based approach that enables more efficient delivery of siRNA drugs is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers (http://www.liebertpub.com). The article is available on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).

Compared to a commonly used lipid-based transport agent, the cSCK nanoparticles described in this article better protected siRNAs from being degraded in the bloodstream and were associated with greater gene silencing efficiency of siRNA drugs.

The study authors, Yuefei Shen, Huafeng Fang, Ke Zhang, and John-Stephen Taylor, Washington University, St. Louis, MO, and Ritu Shrestha and Karen Wooley, Texas A&M University, College Station, TX, attribute the better gene silencing efficiency achieved with cSCKs with improved cell uptake of the siRNAs. They present their findings in the article "Effective Protection and Transfection of siRNA by Cationic Shell-Crosslinked Knedel-Like Nanoparticles (cSCKs)." (http://online.liebertpub.com/doi/full/10.1089/nat.2012.0390)

"The potential of siRNAs as therapeutic agents is immense, but we still have to develop better and more targeted delivery methods for many diseases," says Executive Editor Fintan Steele, PhD, SomaLogic, Inc., Boulder, CO. "The work of Shen and colleagues demonstrates that nanotechnology approaches are rapidly progressing towards the goal of meeting the challenge of delivery."

###

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Fintan Steele, PhD (SomaLogic, Boulder, CO).

About the Journal

Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the Official Journal of the Oligonucleotide Therapeutics Society (http://www.oligotherapeutics.org). Complete tables of content and a free sample issue may be viewed on the Nucleic Acid Therapeutics website (http://www.liebertpub.com/nat).

Read more from the original source:
Nanoparticles boost therapeutic potential of siRNA drugs

Recommendation and review posted by Bethany Smith

Public release date: 11-Apr-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 11, 2013Pulmonary fibrosis is a chronic, deadly disease that affects five million people worldwide. It is irreversible, its cause is poorly understood, and it has a median survival of only about 3 years. A new study that implicates mast cellsan immune cell involved in allergic asthmain the development of idiopathic pulmonary fibrosis could lead to new, more effective therapies. The study is published in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DNA and Cell Biology website at http://www.liebertpub.com/dna.

In the article "Mast Cells: A Pivotal Role in Pulmonary Fibrosis," A. Veerappan and colleagues from Weill Cornell Medical College, New York, NY, showed that in mice unable to produce mast cells, a chemical trigger known to cause pulmonary fibrosis does not result in disease. However, when the researchers introduced mast cells into the lungs of these mice, disease protection was reversed and the mice developed pulmonary fibrosis. The authors identify a role for two key compounds produced by mast cellshistamine and reninand propose that they promote fibrogenesis when mast cells are activated early in the course of the disease.

Editor-in-Chief Carol Shoshkes Reiss, PhD, Departments of Biology and Neural Science, New York University, NY says, "Randi Silver's lab has shown, in this compelling paper, that mast cells contribute to the pathogenesis of pulmonary fibrosis. These observations are important and may lead to the development of new therapeutic modalities to prevent deterioration of lung function."

###

About the Journal

DNA and Cell Biology is the trusted source for authoritative, peer-reviewed reporting on the latest research in the field of molecular biology. By combining mechanistic and clinical studies from multiple systems in a single journal, DNA and Cell Biology facilitates communication among biological sub-disciplines. Coverage includes gene structure, function, and regulation; molecular medicine; cellular organelles; protein biosynthesis and degradation; and cell-autonomous inflammation and host cell response to infection. Complete tables of content and a sample issue may be viewed on the DNA and Cell Biology website at http://www.liebertpub.com/dna.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Antioxidants & Redox Signaling, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Read more:
Mast cells have critical role in initializing pulmonary fibrosis

Recommendation and review posted by Bethany Smith

CARLSBAD, Calif., April 11, 2013 /PRNewswire/ --Life Technologies Corporation (LIFE) today announced the launch of Vector NTI Express Designer, the latest advancement in its Vector NTI software platform, which offers researchers comprehensive and streamlined custom vector and genetic construct design and synthesis. The desktop software tool is designed for molecular biology, metabolic engineering, genetic engineering, and synthetic biology professionals who want to rationally design, assemble and order synthetic genetic "parts," optimizing genetic components for a broad range of applications.

An extension of the Vector NTI software offerings, Express Designer incorporates an integrated gene synthesis service for rapid sequence submission and order placement, effectively building a bridge from DNA sequence to gene synthesis. Customers can use the Express Designer software tools to design custom DNA parts and submit them directly to Life Technologies' GeneArt portal for synthesis.

"Molecular and synthetic biologists can now move from construct design to synthesis faster than ever before," said Nathan Wood, General Manager and Vice President of Synthetic Biology at Life Technologies. "This launch represents a true game changer in the ease, speed and accuracy with which investigators can design and order DNA customized to their needs, as well as the increased confidence they can have that constructs will perform successfully in their experiments."

Vector NTI Express Designer also provides sequence optimization to fine tune expression levels of cloned genes, enables construction of multiple vectors for compatible and simultaneous function, and generates variants from template DNA parts, devices, and circuits more effectively. In addition to designing and ordering custom components, the software also contains an electronic database or "mini electronic lab notebook" that allows researchers to maintain a searchable record of genetic parts, constructs and experimental results that can be referred to and utilized to optimize constructs and circuits.

"The Vector NTI Express Designer will allow us to tackle difficult design challenges in synthetic biology," said Christopher Voigt, Ph.D., associate professor of Biological Engineering at M.I.T. "The software automates and facilitates the design process with an intuitive graphical-user interface where well-characterized and annotated parts can be drag-and-dropped to create standard devices and advanced circuits." Voigt is a leader in the study of circuit design underlying the development of synthetic organisms, a process that requires constructing synthetic multi-gene pathways.

"The power of the Vector NTI Express Designer database is that it allows us to track and analyze our experimental results so that we avoid duplicating effort and focus on getting to the answer more quickly," said Steve Mayfield, Ph.D., professor in the Division of Biological Sciences at the University of California, San Diego. "We can focus more on what we want our constructs to do and less on how to make them do it." Mayfield is a pioneer in the genetic design of organisms such as algae for biofuel production.

Vector NTI Express Designer is built on a the Vector NTI Sequence Analysis and Bioinformatic Tools platform, and so inherits many of the applications associated with that platform, including: sequence analysis and design, annotation, and illustration; molecular biology data management; open reading frame and restriction enzyme analysis and mapping; primer design; recombinant molecule design, including Gateway and TOPO cloning, GeneArt seamless cloning & high-order assembly and gene synthesis.

Built on the trusted history of high-quality sequence analysis and design tools of Vector NTI Software, Vector NTI Express Designer enables rational bio-design on the most popular computing architectures, including native Mac OSX 10.6+, Windows XP, Windows 7, and Windows 8 operating systems. Its plug-in architecture allows users to have confidence that additional features and functionality can be added to the platform and deliver more value over time while its Automatic Updater ensures that users will be automatically notified of updates and given the option to download new or updated plug-ins to always be running the latest, most complete software package available.

For more information, please visit http://www.lifetechnologies.com/vectornti.

All products referenced are for Research Use Only. Not intended for diagnostic uses.

Visit link:
Life Technologies Launches New Bioinformatics Software Platform Enabling Bio-Design and Gene Synthesis from Next ...

Recommendation and review posted by Bethany Smith

Thanks to extensive genetic engineering, drugmakers can now brew large vats of the malaria drug artemisinin, stabilizing the world supply.

For the first time, researchers have successfully engineered a strain of bakers yeast capable of spewing out malaria drugs on an industrial scale. The French pharmaceutical giant Sanofi has already begun brewing the microbes and announced plans to generate 70 million doses this year.

The advance is the result of a 10-year odyssey in synthetic biology, the wholesale engineering of an organisms genetic and metabolic system for practical purposes (see Biologys Master Programmers).Amyris, the biotech startup that engineered the yeast strain, is also developing microbes to produce fragrances and other high-value chemicals.

This is the first synthetic biology project that has been scaled up to industrial manufacturing and will have a real impact in the world, says Jack Newman, chief scientific officer at Amyris. There should never been a shortage of artemisinin ever again.

Amyris had already engineered yeast capable of producing artemisinic acid, the precursor to the drug (see Cheaper Malaria Drugs). But the most recent advance, published today in Nature, dramatically improved the yield from 1.6 grams per liter to 25 grams per liter.

The improvement primarily comes from the discovery of three key enzymes in sweet wormwood, the plant that naturally produces artemisinin, which researchers then introduced to yeast.

Artemisinin is the primary ingredient in artemisinin combination therapies, the World Health Organizations preferred malaria treatment. But because the drug is primarily derived from plants, its costs can vary from $350 to $1200 per kilogram of the active ingredient.

The botanical supply is inconsistent for various reasons, including weather and incentives for farmers, says Ponni Subbiah, global program leader for drug development at OneWorld Health, a nonprofit drug development organization that funded the research through a grant from the Gates Foundation.

The synthetic process can run year round and takes about three months, compared to 15 months for plant-based methods. Our aim is to stabilize the supply independent of the plant supply, says Chris Paddon, who leads the artemisinin project at Amyris.

OneWorldHealth has licensed the technology to Sanofi, which has already produced nearly 40 tons of the artemisinic acid. (The acid is then chemically converted into artemisinin.) Sanofi aims to produce 60 tons of the material next year approximately 120 million courses of treatment and has pledged to sell it without profit.

Original post:
Microbes Can Mass-Produce Malaria Drug

Recommendation and review posted by Bethany Smith

Medical Association Foundation Fundraising Video

By: minimattersllc

Read more:
Medical Association Foundation Fundraising Video - Video

Recommendation and review posted by Bethany Smith

Public release date: 11-Apr-2013 [ | E-mail | Share ]

Contact: Jenny Eriksen jenny.eriksen@bmc.org 617-638-6841 Boston University Medical Center

(Boston) Researchers from Boston University School of Medicine (BUSM) have pinpointed a genetic signature for chronic obstructive pulmonary disease (COPD) from airway cells harvested utilizing a minimally invasive procedure. The findings provide a novel way to study COPD and could lead to new treatments and ways to monitor patient's response to those treatments. The study is published online in the American Journal of Respiratory and Critical Care Medicine.

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that leads to the loss of lung function primarily caused by cigarette smoking. It causes coughing, wheezing, shortness of breath, chest tightness and other symptoms that make it difficult to breathe. While there are treatments and lifestyle changes that can help people cope with COPD, there currently is no cure and there are no effective therapies to reduce the rate of lung function decline. According to the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI), which partially funded the study, COPD is the third leading cause of death in the United States, resulting in approximately 135,000 deaths each year.

"There have been limited molecular studies of COPD given the inaccessibility and invasiveness of obtaining lung tissue," said Katrina Steiling, MD, MSc, assistant professor of medicine at BUSM who served as the study's first author. The researchers hypothesized that while COPD primarily affects the tissue deep within the lung, the effects of COPD might be detectable in relatively accessible tissue throughout the respiratory tract. This echoes previous work they had done that found that cancer found deep in the lung could be detected by cancer-specific patterns of gene expression in the largest airways connected to the windpipe, far from the tumor.

To examine their hypothesis, the research team used airway cells obtained during a bronchoscopy, a procedure that involves putting a small camera into the airway through the nose or mouth. During the procedure, which can be done while a patient is awake under local anesthesia or moderate sedation, a cytology brush is used to gently scrape the sides of airways to collect cells.

They examined 238 samples from current and former smokers that had been collected by Stephen Lam, MD, a collaborator from the University of British Columbia. Eighty seven of the samples were from patients who had been diagnosed with mild to moderate COPD based on their lung function. The other 151 samples represented patients who did not have COPD based on these criteria.

When the researchers compared the airway samples from both groups, they found that 98 genes were expressed at different levels in those diagnosed with COPD compared to those without COPD. In order to determine how similar the airway cell changes were to lung tissue cells, the researchers compared their results with previously published findings on the gene expression changes associated with COPD in lung tissue. The results of the comparison demonstrate that the changes that occur in the airway cell samples in those diagnosed with COPD were similar to the changes in lung tissue cells of individuals with the disease despite the airway cells coming from regions of the lung not thought to be altered by disease.

"Our data shows that there are consistent gene-expression changes that occur in both airway and lung tissue cells in individuals with COPD," said Avrum Spira, MD, MSc, Alexander Graham Bell professor of medicine and chief of the division of computational biomedicine at BUSM who served as one of the senior co-authors of the study.

To investigate the effects of treatment on the COPD-associated gene expression changes, the researchers collaborated with a team led by Maarten van den Berge, MD, PhD, from the University of Groningen Medical Center in the Netherlands that had collected airway cells from COPD patients before and after they started steroid therapy. They found that the expression of some genes that changed due to COPD reversed their expression after treatment and started to look more like the levels seen in current or former smokers without COPD.

Read the original:
BUSM researchers identify novel approach to study COPD and treatment efficacy

Recommendation and review posted by Bethany Smith

Each cancer patients response to chemotherapy is unique. Some may experience nausea and immune deficiency, while others can experience a more severe adverse condition known as chemotherapy-induced peripheral neuropathy (CIPN) a form of nerve damage that can be so debilitating, it often prompts patients to stop treatment early.

Doctors have had a hard time predicting which patients will ultimately develop CIPN, making it difficult to tailor treatment so that it is most effective for each individual. But now, new research has revealed seemingly benign genetic mutations that may influence who develops this painful side effect.

In a study from the Mayo Clinic Cancer Center, researchers have implicated the genes EPHA5, ARHGEF10 and PRX as playing significant roles in the development of CIPN. This discovery can ultimately help doctors to have a better understanding of CIPN and whether or not their patients should move forward with certain cancer treatments.

Chemotherapy-induced peripheral neuropathy is one of the most important, unmitigated side effects of chemotherapy, lead author Dr. Andreas Beutler, an oncologist at the Mayo Clinic Cancer Center, told FoxNews.com. You have some other side effects that used to be very important such as nausea and immune deficiency but special medications have been developed. With CIPN, it has actually become the most prominent and troubling side effect for many chemotherapy patients, because there is no medication for it.

Peripheral neuropathy is caused by damage to the peripheral nerves, which are furthest away from the brain and spinal cord. When chemotherapy damages these nerves, the condition becomes CIPN. Symptoms vary in type and intensity depending on which peripheral nerves are damaged, but they typically include shooting pain, burning, tingling or electric shock-like pain, loss of feeling, balance issues and muscle weakness. The symptoms can become so severe that patients lose the ability to walk normally and are left with permanent numbness in their extremities.

CIPN affects an estimated 30 to 40 percent of patients, but there is no current way to determine who will experience it or how severe it will be.

Beutler and his colleagues decided to analyze the genetics of cancer patients through exome sequencing - a form of DNA analysis that selectively sequences the parts of the genome responsible for coding functional proteins. Known as the exonic region, this area is estimated to house 85 percent of all disease-causing genetic mutations.

The researchers performed exome sequencing on 20,794 genes from 119 cancer patients. Half of the patients were experiencing CIPN during their chemotherapy trial.

The genome is three billion nucleotides, meaning the whole genome has three billion different positions, Beutler said. Out of those, we assessed 60 million of each patient that are best understood the exome. Thereby, we could get a very good view of the part of the genome that is most important and most relevant to our question.

Exome sequencing of the more than 20,000 genes lead the researchers to EPHA5 a previously implicated gene in hereditary peripheral neuropathy as well as two new genes ARHGEF10 and PRX. Genetic mutation in all three areas was associated with a predisposition to CIPN.

View post:
Genetic mutations may predict who will develop chemotherapy side effects

Recommendation and review posted by Bethany Smith

Public release date: 11-Apr-2013 [ | E-mail | Share ]

Contact: Matt Fearer fearer@wi.mit.edu 617-452-4630 Whitehead Institute for Biomedical Research

CAMBRIDGE, Mass. (April 11, 2013) In a surprising finding that helps explain fundamental behaviors of normal and diseased cells, Whitehead Institute scientists have discovered a set of powerful gene regulators dubbed "super-enhancers" that control cell state and identity. Healthy cells employ these super-enhancers to control genes responsible for cellular functions and developmental transitionssuch as that from embryonic stem cell to nerve cellbut cancer cells are able to assemble their own insidious super-enhancers to overproduce harmful oncogenes that lead to aggressive tumors.

"We have been marveling at the complexity of cellular control, with millions of enhancers controlling tens of thousands of genes in the vast array of cells that comprise human beings," says Whitehead Member Richard Young. "So it was a surprise to find that only a few hundred super-enhancers control most key genes that give each cell its special properties and functions, and furthermore, that these special controls are hijacked in cancer and other diseases."

The findings are described in dual papers from Young and collaborators at Dana-Farber Cancer Institute published together in the April 11 edition of the journal Cell.

In the first work, the Young lab establishes a model of gene regulation in normal cells that appears to be dramatically less complex and more solvable than previously thought. To date, a vast body of researchincluding that of the recently described ENCODE (Encyclopedia of DNA Elements) projecthas identified more than one million enhancers or "switches" that control gene expression in mammalian cells. Deciphering the precise function and target gene for each of these switches will be a daunting task, but Young and colleagues have found something of a shortcut to solving the core gene control circuitry. They show that only a few hundred special switchesthat is, super-enhancerscontrol the key genes that actually make each cell different.

"What is fantastic about this concept is its simplicity," notes Denes Hnisz, a Young lab postdoctoral scientist and a co-author of the first Cell paper. "We found that genes that are especially important for each cell are regulated by these specialized enhancers. But we also discovered that the super-enhancers are especially quick to change during development, and thus loss of old super-enhancers and establishment of new ones drives cell identity changes during development."

Young says such changes in cell identity probably begin and end with the super-enhancers, which, though powerful, are also exquisitely sensitive to alterations in their environment. In fact, as differentiation begins, active super-enhancers are decommissioned, leading to changes in gene expression programs that fall under the control of newly established super-enhancers. It's a process that adds remarkable insight to our understanding of how a fertilized egg eventually gives rise to the more than one trillion cells of the human body.

"The discovery of super-enhancers promises to help us solve the regulatory circuitry of all human cells," Young says. That includes cancer cells.

While mapping the locations of super-enhancers along the genome of multiple myeloma (MM) cells, which are especially aggressive blood cancer cells, Young lab scientists found them in areas associated with known cancer-causing genes, including the notorious MYC oncogene. It turns out these MM cells were forming their own super-enhancers to drive dangerous overexpression of their oncogenes. Moreover, this phenomenon was not limited to MM cells, as the researchers identified super-enhancers at key tumor genes in small-cell lung cancer and the brain cancer glioblastoma multiforme.

Read more:
Genetic master controls expose cancers' Achilles' heel

Recommendation and review posted by Bethany Smith

Is the Human Mind Unique?--Archaeological Evidence;Desperately Seeking Explanation;Moral Sense
Visit: http://www.uctv.tv/) Cognitive abilities often regarded as unique to humans include humor, morality, symbolism, creativity, and preoccupation with th...

By: UCtelevision

See the rest here:
Is the Human Mind Unique?--Archaeological Evidence;Desperately Seeking Explanation;Moral Sense - Video

Recommendation and review posted by Bethany Smith

UNIVERSAL THEORY "Mystery Timeline" Album Promo Video
UNIVERSAL THEORY "Mystery Timeline" Full length album out on Metal Hell Records in May 2013 CD/ MP3 and Limited Edition vinyl LP.

By: MetalHellRecords

View original post here:
UNIVERSAL THEORY "Mystery Timeline" Album Promo Video - Video

Recommendation and review posted by Bethany Smith

#1581; #1604; #1605; #1608; #1575; #1605; #1604;

By: Roy James

The rest is here:
حلم وامل - Video

Recommendation and review posted by Bethany Smith

Carlos Polo - por que te ame

By: Gilbert Camana

Read more from the original source:
Carlos Polo - por que te ame - Video

Recommendation and review posted by Bethany Smith

Debut Of DNA Genetics Exodus Kush
DNA Genetics Exodus Kush is looking great in the marijuana flowering space. Didn #39;t grow as much as I expected when thrown into flowering, but has turned into...

By: Matt Mernagh

See the rest here:
Debut Of DNA Genetics Exodus Kush - Video

Recommendation and review posted by Bethany Smith

State of Decay Update, Release Date (Which there is none), Storyline, And Basic Overview
If you enjoyed this video please SUBSCRIBE. bull;Check me out on TWITTER @KOMODOMOJO for up to date uploads. bull;If you have any questions please do not be afraid ...

By: KomodoMojo

More:
State of Decay Update, Release Date (Which there is none), Storyline, And Basic Overview - Video

Recommendation and review posted by Bethany Smith

How To Put Flat Bands On The PFS, Pickle Fork Shooter
This simple method for any forked shooter. Tex flat bands are the Best and give Raycarl #39;s pouches a try.

By: pfshooter

Read the original post:
How To Put Flat Bands On The PFS, Pickle Fork Shooter - Video

Recommendation and review posted by Bethany Smith

The Kojaks - "Let #39;s let the flow flow"
Video de The Kojaks tocando en directo su tema "Let #39;s let flow flow" en la sala Loco Club de Valencia. Os mandamos un fuerte abrazo a toda la familia kojak, ...

By: TheKojaksBand

See the article here:
The Kojaks - "Let's let the flow flow" - Video

Recommendation and review posted by Bethany Smith

DNA Vergadering 09-04-2013

By: dnasuriname

Read more here:
DNA Vergadering 09-04-2013 - Video

Recommendation and review posted by Bethany Smith

Seattle Genetics Inc. ( SGEN ) recently presented data on its antibody-drug conjugate (ADC) candidates at the annual meeting of the American Association for Cancer Research (AACR).

Preclinical data on SGN-CD33A showed significant antitumor activity in acute myeloid leukemia (AML) models. Seattle Genetics intends to file an investigational new drug (IND) application and start a phase I study in 2013.

Another candidate, SGN-LIV1A, showed encouraging pre-clinical data for breast cancer. Seattle Genetics will file an IND application for SGN-LIV1A as well and start a phase I study in 2013 for breast cancer.

Seattle Genetics' sole marketed ADC product is Adcetris. Adcetris is used for the treatment of patients with Hodgkin's lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris is also approved for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen.

Adcetris was approved by the US Food and Drug Administration (FDA) in Aug 2011, got EU approval in Oct 2012 and marketing authorization in Canada in Feb 2013.

ADCs have been attracting a lot of interest of late with major companies entering into collaborations. Seattle Genetics has collaborations with companies like Roche Holding AG 's ( RHHBY ) Genentech for the development of ADCs.

A few days back, Astellas Pharma, Inc. ( ALPMY ) announced a deal with Ambrx Inc. for the discovery and development of novel ADCs.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now Cleveland BioLabs, Inc. ( CBLI ) looks more attractive with a Zacks Rank #1 (Strong Buy).

ASTELLAS PHARMA (ALPMY): Get Free Report

CLEVELAND BIOLB (CBLI): Free Stock Analysis Report

Read the original:
ADC Data from Seattle Genetics - Analyst Blog

Recommendation and review posted by Bethany Smith

Hawkes Bay paralympian, Gavin Foulsham has an exciting new challenge ahead of him as the new CEO of the worlds largest red meat genetics company, Focus Genetics.

For the past four years, Mr Foulsham has worked as the general manager of the Farmlands Card, where his focus has been to engage shareholders. During this time the turnover of the business increased by $100 million.

Mr Foulsham spent several years working as general manager of MoleMap, a high growth New Zealand technology company. He successfully ran the New Zealand business before launching the brand in Australia.

The new CEO also has a rural background, having grown up on a farm in the Nelson region.

"I am really excited about the opportunity to play a big role in shaping the future of New Zealands red meat genetics. I grew up on a farm so I have been around animals for a long time. I have connected with a lot of farmers during my time at Farmlands. I love dealing with the guys who work the land. They call a spade a spade and thats what heartland New Zealand is all about," said Mr Foulsham.

Focus Genetics Chairman, Andy Pearce says Mr Foulshams rural background, combined with his experience working in science and technology sets him up well to lead Focus Genetics into the future.

"Gavins technical sales and distribution experience will be highly valued. He is also well connected with farmers so we look forward to working with him."

Mr Foulshams a former Paralympian wheelchair racer, having represented New Zealand at the 1992 Barcelona Paralympics and Sydney in 2000 where he finished fifth in the 800m and ninth in the marathon. He is the New Zealand title holder for Para Rowing and has also completed the Boston Marathon and Coast to Coast.

Last year, Mr Foulsham missed out on selection for the London Paralympics. He had aimed to be part of the NZ Double Scull Para Rowing Crew.

"My involvement in sport has taught me a great deal that I use in business. I know how important planning is for success, and Im looking forward to learning more about genetics and helping Focus Genetics implement a plan to drive the next stage of growth"

View original post here:
Focus Genetics appoints CEO

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced it has closed its initial public offering of 690,000 shares of common stock (including 90,000 shares that were offered and sold by Cancer Genetics pursuant to the exercise in-full of the underwriters over-allotment option) at a price to the public of $10.00 per share. Total gross proceeds from the offering were $6,900,000, before deducting underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Aegis Capital Corp. acted as sole book-running manager for the offering.

Feltl and Company, Inc. acted as co-manager for the offering.

This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.

Continued here:
Cancer Genetics, Inc. Announces Closing of Initial Public Offering of 690,000 Shares of Common Stock

Recommendation and review posted by Bethany Smith